Alia Therapeutics
MILAN, ITALY / ACCESSWIRE / May 5, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Letizia Goretti as Chief Executive Officer (CEO) and Board Director, effective immediately.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Letizia, who is joining Alia from Johnson & Johnson, has more than 25 years of international experience in life sciences. She brings a broad background in strategic, operational, R&D, and commercial activities across the sector, and a track record of building strong partnerships and delivering sustainable value to stakeholders and patients.
In her previous role as Senior Director, Transactions and Alliances at the Johnson & Johnson Innovation Centre in London, she led strategic partnering efforts with academia, entrepreneurs, industries, governmental organizations, and charities, focusing on the development and adoption of genomics and digital capabilities for discovery and development.
"Letizia's appointment as CEO marks an important step forward for Alia," said Paola Pozzi, a Partner at Sofinnova Partners. "Her all-round experience and leadership skills, combined with her drive to create value through innovation, will be a great catalyst to accelerate Alia's growth."
"I am fascinated by the opportunity to work with a team of cutting-edge scientists on a quest to develop its innovative platform for CRISPR-based medicine," Letizia said. "We are enabling novel gene editing strategies designed to overcome current limitations and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
"Our Board of Directors is thrilled to appoint a leader like Letizia," said Silvano Spinelli, Chairman of the Board of Directors. "With her broad background and track record of value creation, she is well positioned to guide Alia into a bright future."
Letizia holds a M.Sc. in Chemistry from the University of Perugia. She started her career at Bristol-Myers Squibb in Italy before moving to The Janssen Pharmaceutical Companies, a unit of Johnson & Johnson, where she held several roles with increasing responsibilities and international scope in business development, CMC development, commercial life cycle management and global new product launches.
In April, Alia announced a €4.4 million seed financing extension led by Sofinnova Partners through the Sofinnova Telethon Fund. Other investors included Indaco Bio and a group of Italian investors brought together by Banor SIM and Banca Profilo.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753018/Alia-Therapeutics-names-Letizia-Goretti-as-Chief-Executive-Officer
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Foundations of Neutrinovoltaics: From Shared Knowledge to Shared Future4.9.2025 20:08:00 CEST | Press release
Uniting Mathematics, Artificial Intelligence, and Neutrino Science into a New Energy Paradigm BERLIN, DE / ACCESS Newswire / September 4, 2025 / Every technological leap builds on decades of knowledge. Neutrinovoltaics is no exception. Its foundation lies in the convergence of three intellectual streams, mathematics, artificial intelligence, and neutrino science, that together redefine how electricity can be generated.Holger Thorsten Schubart on Shared Science Celebrating the science that powers neutrinovoltaics The governing formula formalizes this principle: P(t) = η · ∫V Φ_eff(r,t) · σ_eff(E) dV It shows in precise terms how efficiency, flux density, interaction cross-section, and material volume convert invisible radiation into usable current. What once was intangible now has calculable structure. Holger Thorsten Schubart: Visionary and Bridge-Builder At the center of this development stands Holger Thorsten Schubart, mathematician and CEO of Neutrino® Energy Group. For over a decad
LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka4.9.2025 18:50:00 CEST | Press release
AMSTERDAM, NETHERLANDS / ACCESS Newswire / September 4, 2025 / LOLC Advanced Technologies (LOLC AT), a fully owned subsidiary of LOLC Holdings PLC, together with Corsair Group International, headquartered in Amsterdam, has announced a landmark partnership to upgrade and expand LOLC AT's existing waste-to-fuel plant at Kerawalapitiya. This strategic initiative aims to address Sri Lanka's growing plastic and polythene waste challenge. With Sri Lanka generating an estimated 7,000 metric tons of solid waste per day, equating to roughly 2.56 million metric tons per year, a significant portion of which consists of polythene and plastic. Plastic pollution has become one of the nation's most pressing environmental concerns, with much of this waste ends up in overflowing landfills, waterways, and oceans, posing serious threats to ecosystems, public health, and tourism. LOLC AT invested in and commissioned a waste-to-fuel plant in 2023, which it has successfully operated throughout 2024. This fa
MicroVision Appoints Glen DeVos as Chief Executive Officer4.9.2025 15:20:00 CEST | Press release
REDMOND, WA / ACCESS Newswire / September 4, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that the Company's Board of Directors has appointed Glen W. DeVos as Chief Executive Officer and a member of the Company's Board of Directors effective September 30, 2025. Sumit Sharma, the Company's current CEO, will remain in the role through the effective date to ensure a smooth transition. A seasoned executive, DeVos brings more than three decades of leadership in the automotive and industrial technology sectors, delivering advanced technologies and solutions with a focus on autonomy and mobility. Since 1992, DeVos served in various business leadership and technology roles at Aptiv, and its predecessor Delphi Automotive, including as Aptiv's Chief Technology Officer and President of the Advanced Safety and User Experience business unit. His extensive experience developing and driving strategy, le
U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club4.9.2025 13:00:00 CEST | Press release
Global Sports Brand Marks Eighth Year Partnering with the Iconic West Coast Polo Club SANTA BARBARA, CA AND WEST PALM BEACH, FL / ACCESS Newswire / September 4, 2025 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly marked a major milestone this past weekend as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, held August 15-31 at the iconic Santa Barbara Polo & Racquet Club. This prestigious tournament, known as the crown jewel of West Coast polo, brought together top-tier talent and record-breaking crowds for one of the sport's most celebrated events.U.S. Polo Assn. Pacific Coast Open Photo Credit: Michelle Lauren For the first time, U.S. Polo Assn. served as the Title Sponsor of the 2025 U.S. Polo Assn. Pacific Coast Open, one of the oldest and most revered polo tournaments in the world, dating back to 1908. As part of a broader partnership, U.S. Polo Assn. also served as the Official Apparel Brand and Stadium Sponsor
Clean Air Metals Confirms Potential Major Extension at Escape Deposit Along 2.5 km Magnetic Trend4.9.2025 13:00:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 4, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to report that it has intersected over 50 m of magmatic sulphide mineralization in the Escape ultramafic conduit at a depth of 400 m (Image 1). The intersection was observed in core from drill hole EL25-001, located approximately 350 m from the current limits of the Escape Deposit ("Escape"). The target was the first of several coincident magnetic and electromagnetic anomalies to be drilled in the eastern half of the Escape conduit. The new intersection opens up 2.5 km of prospective geophysical targets and provides a critical new opportunity to expand the existing mineral inventory1 in the Thunder Bay North ("TBN") project, which compliments the Company's focus on advancing the project to potentially become a significant critical minerals producer of Cu, Pt, Pd and Ni. Assay results are expected to be available in the coming we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom